Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV vaccination

PLoS Pathogens

17, e1010022

DOI: 10.1371/journal.ppat.1010022

Citation Report

#	Article	IF	Citations
1	The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Brazilian Journal of Infectious Diseases, 2021, 25, 101606.	0.6	94
2	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. Clinical Infectious Diseases, 2022, 74, 734-742.	5.8	88
3	Development and preclinical evaluation of virusâ€like particle vaccine against COVIDâ€19 infection. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 258-270.	5.7	27
4	Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case. International Journal of Infectious Diseases, 2021, 110, 232-234.	3.3	21
5	Persistence of neutralizing antibodies a year after SARSâ€CoVâ€2 infection in humans. European Journal of Immunology, 2021, 51, 3202-3213.	2.9	76
6	SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166264.	3.8	5
7	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection, 2022, 28, 202-221.	6.0	569
8	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine, 2021, 27, 2127-2135.	30.7	450
11	The dynamic change of SARS-CoV-2 variants in Sierra Leone. Infection, Genetics and Evolution, 2022, 98, 105208.	2.3	5
12	Meharry Medical College Mobile Vaccination Program: Implications for Increasing COVID-19 Vaccine Uptake among Minority Communities in Middle Tennessee. Vaccines, 2022, 10, 211.	4.4	20
16	Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. Journal of Hematology and Oncology, 2022, 15, 3.	17.0	28
18	Omicron (B.1.1.529) variant of SARSâ€CoVâ€2: Concerns, challenges, and recent updates. Journal of Medical Virology, 2022, 94, 2336-2342.	5.0	75
19	SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies. Journal of Clinical Investigation, 2022, 132, .	8.2	30
23	Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies. SSRN Electronic Journal, 0, , .	0.4	0
24	Selection of Optimum Formulation of RBD-Based Protein Sub-Unit Covid19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies. SSRN Electronic Journal, 0, , .	0.4	0
25	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. Pathogens, 2022, 11, 275.	2.8	9
26	Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis. Vaccines, 2022, 10, 277.	4.4	15
27	Neutralization of SARS-CoV-2 Variants by rVSV-Î”G-Spike-Elicited Human Sera. Vaccines, 2022, 10, 291.	4.4	19

#	Article	IF	Citations
31	Conserved Pattern and Potential Role of Recurrent Deletions in SARS-CoV-2 Evolution. Microbiology Spectrum, 2022, 10, e0219121.	3.0	9
33	Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. Microbiology Spectrum, 2022, 10, e0270221.	3.0	3
34	SARSâ€CoVâ€2 and its variants of concern including Omicron: A never ending pandemic. Chemical Biology and Drug Design, 2022, 99, 769-788.	3.2	37
35	Virtual healthcare services and digital health technologies deployed during coronavirus disease 2019 (COVID-19) pandemic in South Africa: a systematic review. Global Health Journal (Amsterdam,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.0	78
36	Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. Clinical Immunology, 2022, 238, 108999.	3.2	10
37	Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS ONE, 2022, 17, e0266852.	2.5	49
38	Experimental veterinary SARS-CoV-2 vaccine cross neutralization of the Delta (B.1.617.2) variant virus in cats. Veterinary Microbiology, 2022, 268, 109395.	1.9	6
40	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Human Vaccines and Immunotherapeutics, 2022, 18, 1-12.	3.3	10
41	Control of common viral epidemics but not of SARS-CoV-2 through the application of hygiene and distancing measures. Journal of Clinical Virology, 2022, 150-151, 105163.	3.1	6
42	Reverse vaccinology approach for multi-epitope centered vaccine design against delta variant of the SARS-CoV-2. Environmental Science and Pollution Research, 2022, 29, 60035-60053.	5.3	13
43	Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. EBioMedicine, 2022, 78, 103944.	6.1	119
44	Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics.. Acta Biomedica, 2022, 93, e2022179.	0.3	9
45	In Silico Analysis Predicts a Limited Impact of SARS-CoV-2 Variants on CD8 T Cell Recognition. Frontiers in Immunology, 2022, 13, 891524.	4.8	0
46	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. Translational Research, 2022, 248, 11-21.	5.0	13
47	Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months. Frontiers in Immunology, 2022, 13, 879036.	4.8	13
49	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nature Communications, 2022, 13, 2670.	12.8	108
50	SARS-CoV-2 Omicron variant escapes neutralizing antibodies and TÂcell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Reports Medicine, 2022, 3, 100651.	6.5	24
51	SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status. Nature Communications, 2022, 13, 2777.	12.8	8

#	Article	IF	Citations
52	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. Indian Journal of Medical Research, 2022, 155, 105.	1.0	2
53	SARS-COV-2 RBD (Receptor binding domain) mutations and variants (A sectional-analytical study). Microbial Pathogenesis, 2022, 168, 105595.	2.9	16
54	Investigating COVID-19 Vaccine Impact on the Risk of Hospitalisation through the Analysis of National Surveillance Data Collected in Belgium. Viruses, 2022, 14, 1315.	3.3	0
55	Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review. Vaccines, 2022, 10, 909.	4.4	6
56	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. Viruses, 2022, 14, 1232.	3.3	2
57	Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. Scientific Reports, 2022, 12, .	3.3	13
58	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. Viruses, 2022, 14, 1255.	3.3	30
59	SPEAR: Systematic ProtEin AnnotatoR. Bioinformatics, 2022, 38, 3827-3829.	4.1	1
60	Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection. Clinical Microbiology and Infection, 2022, 28, 1629-1635.	6.0	12
61	Modeling pandemic to endemic patterns of SARS-CoV-2 transmission using parameters estimated from animal model data. , 2022, 1, .		7
62	Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nature Communications, 2022, 13, .	12.8	53
63	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 2022, 7, 1161-1179.	13.3	352
64	Differential avidity determination of IgG directed towards the receptorâ€binding domain (RBD) of SARSâ€CoVâ€2 wildtype and its variants in one assay: Rational tool for the assessment of protective immunity.. Journal of Medical Virology, 0, , .	5.0	6
65	Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. BMJ, The, 0, , e071249.	6.0	31
66	Post-vaccination T cell immunity to omicron. Frontiers in Immunology, 0, 13, .	4.8	20
67	High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020â€“2021. Frontiers in Medicine, 0, 9, .	2.6	6
68	SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients â€“ a comparative long term post-infection study. Frontiers in Immunology, 0, 13, .	4.8	4
70	Immune response to third SARSâ€CoVâ€2 vaccination in seronegative kidney transplant recipients: Possible improvement by mycophenolate mofetil reduction. Clinical Transplantation, 2022, 36, .	1.6	14

#	Article	IF	Citations
71	SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity. Journal of Infectious Diseases, 2022, 227, 40-49.	4.0	6
73	Inactivated vaccine injection and immunoglobulin G levels related to severe coronavirus disease 2019 (Delta) pneumonia in Xiâ€™an, China: A single-centered, retrospective, observational study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	2
74	Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. Polymers, 2022, 14, 3263.	4.5	3
75	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. Nature Communications, 2022, 13, .	12.8	12
76	Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people. Cell Reports Medicine, 2022, 3, 100739.	6.5	5
77	Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design. Scientific Reports, 2022, 12, .	3.3	6
78	Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. EBioMedicine, 2022, 83, 104217.	6.1	44
79	Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. International Journal of Biological Macromolecules, 2022, 219, 980-997.	7.5	28
80	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. International Immunopharmacology, 2022, 111, 109128.	3.8	9
81	Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	7
82	Will New Variants Emerge after Delta and Omicron?. , 2022, 13, 1317.		1
83	COVID-19 Severity and Mortality after Vaccination against SARS-CoV-2 in Central Greece. Journal of Personalized Medicine, 2022, 12, 1423.	2.5	6
84	A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection. Journal of Virology, 2022, 96, .	3.4	10
85	Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. Frontiers in Immunology, 0, 13, .	4.8	7
86	Monobiotinylated Proteins Tethered to Microspheres for Detection of Antigen-Specific Serum Antibodies. Journal of Biological Methods, 2022, 9, e164.	0.6	0
88	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. Nature Communications, 2022, 13, .	12.8	11
89	Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants. Protein Journal, 2022, 41, 457-467.	1.6	0
90	Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152). IJID Regions, 2022, 5, 104-110.	1.3	4

#	Article	IF	Citations
91	Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern. Npj Vaccines, 2022, 7, .	6.0	12
92	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. Journal of Pharmaceutical Analysis, 2023, 13, 1-10.	5.3	1
94	Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern. International Journal of Molecular Sciences, 2022, 23, 12267.	4.1	9
95	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. Infectious Diseases, 0, , .	4.0	0
96	Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro. Computers in Biology and Medicine, 2022, , 106284.	7.0	3
97	A comparison of the protective effect of vaccination and clinical features between the SARS-CoV-2 wild-type strain and Delta (B.1.617.2) variant. Archives of Medical Science, 2022, 18, 1678-1682.	0.9	1
98	Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort. Emerging Microbes and Infections, 2023, 12, .	6.5	4
99	The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines, 2022, 10, 1926.	4.4	29
101	Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice. Viruses, 2022, 14, 2584.	3.3	6
102	SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. Biomolecules, 2022, 12, 1742.	4.0	6
103	Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics. Journal of Molecular Biology, 2023, 435, 167928.	4.2	24
104	SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine, 2023, 87, 104402.	6.1	45
106	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. Scientific Reports, 2022, 12, .	3.3	5
107	Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. Vaccines, 2022, 10, 2111.	4.4	1
108	The Delta variant wave in Tunisia: Genetic diversity, spatio-temporal distribution and evidence of the spread of a divergent AY.122 sub-lineage. Frontiers in Public Health, 0, 10, .	2.7	3
109	SARS-CoV-2 Omicron Variant Genomic and Phylogenetic Analysis in Iraqi Kurdistan Region. Genes, 2023, 14, 173.	2.4	1
110	Detection and Molecular Characterization of the SARS-CoV-2 Delta Variant and the Specific Immune Response in Companion Animals in Switzerland. Viruses, 2023, 15, 245.	3.3	7
111	SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nature Reviews Microbiology, 0, , .	28.6	160

#	Article	IF	Citations
112	A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases. British Journal of Dermatology, 2023, 188, 268-277.	1.5	4
113	Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. Medical Microbiology and Immunology, 2023, 212, 103-122.	4.8	18
114	Genomic epidemiology of SARS- CoV-2 Omicron variants in the Republic of Korea. Scientific Reports, 2022, 12, .	3.3	13
115	Modeling identifies variability in SARS-CoV-2 uptake and eclipse phase by infected cells as principal drivers of extreme variability in nasal viral load in the 48Âh post infection. Journal of Theoretical Biology, 2023, 565, 111470.	1.7	5
116	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon, 2023, 9, e13952.	3.2	28
117	A Risk Factor Analysis of SARS-CoV-2 Infection in Animals in COVID-19-Affected Households. Viruses, 2023, 15, 731.	3.3	3
118	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. Viruses, 2023, 15, 856.	3.3	10
119	Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. Viruses, 2023, 15, 944.	3.3	19
120	A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. Communications Biology, 2023, 6, .	4.4	2
121	VSV-Î”G-Spike Candidate Vaccine Induces Protective Immunity and Protects K18-hACE2 Mice against SARS-CoV-2 Variants. Viruses, 2023, 15, 1364.	3.3	0
122	Genome characterization based on the Spike-614 and NS8-84 loci of SARS-CoV-2 reveals two major possible onsets of the COVID-19 pandemic. PLoS ONE, 2023, 18, e0279221.	2.5	2
123	Fitness, growth and transmissibility of SARS-CoV-2 genetic variants. Nature Reviews Genetics, 2023, 24, 724-734.	16.3	12
124	Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants. Medical Microbiology and Immunology, 2023, 212, 291-305.	4.8	4
125	In vitro and in vivo effects of Pelargonium sidoides DC. root extract EPsÂ® 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2. Frontiers in Pharmacology, 0, 14, .	3.5	3
126	Increase in SARS-CoV-2 Seroprevalence in UK Domestic Felids Despite Weak Immunogenicity of Post-Omicron Variants. Viruses, 2023, 15, 1661.	3.3	3
127	SARS-CoV-2 in Domestic UK Cats from Alpha to Omicron: Swab Surveillance and Case Reports. Viruses, 2023, 15, 1769.	3.3	1
128	Repetitive mRNA vaccination is required to improve the quality of broad-spectrum antiâ€“SARS-CoV-2 antibodies in the absence of CXCL13. Science Advances, 2023, 9, .	10.3	0
129	Antibody correlates of protection against Delta infection after vaccination: A nested case-control within the UK-based SIREN study. Journal of Infection, 2023, 87, 420-427.	3.3	2

#	Article	IF	Citations
130	COVID Vaccination as a Strategy for Cardiovascular Disease Prevention. Current Cardiology Reports, 2023, 25, 1327-1335.	2.9	2
131	Dynamics of water-mediated interaction effects on the stability and transmission of Omicron. Scientific Reports, 2023, 13, .	3.3	0
132	Estimating COVID-19 vaccine protection rates via dynamic epidemiological modelsâ€”a study of 10 countries. Annals of Applied Statistics, 2023, 17, .	1.1	0
134	Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet, The, 2023, 402, 2075-2076.	13.7	4
135	The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study. Vaccine, 2024, 42, 53-58.	3.8	0
137	Rational prediction of immunogenicity clustering through crossâ€reactivity analysis of thirteen SARSâ€CoVâ€2 variants. Journal of Medical Virology, 2024, 96, .	5.0	0
138	Impact on the time elapsed since SARS-CoV-2 infection, vaccination history, and number of doses, on protection against reinfection. Scientific Reports, 2024, 14, .	3.3	0